MIVI Neuroscience has recently confirmed that the first patient has been enrolled in the Investigational Device Exemption EVAQ Clinical Study, which has been approved by the U.S. FDA. The enrollment was done in Toulouse, France at Hôpital de Purpan. The trial is a nulti-center, prospective single arm strudy for evaluating the MIVI Q Revascularization System targeting neurointervention in acute ischemic stroke.
The study sites for this EVAQ clinical trial are situated in the U.S. and France. Based on the innovative design of the Q Aspiration Catheter, the Q Revascularization System is able to leverage the larger lumen of the Super 90 8F Guide Catheter for aspiration.